People | 14 February 2023
Sanofi announces change in R&D leadership
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
A pharma industry veteran with over three decades of experience in domestic as well as international markets
He is a Chartered Accountant with more than 19 years of extensive experience
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Surana is a chartered accountant with an all-India rank.
He has published more than 100 research papers in several prestigious national and international journals
Allam was serving recently as the CEO at Public Investment Fund
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Sanjeev is currently the Country President for AstraZeneca Malaysia
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Subscribe To Our Newsletter & Stay Updated
